Moderna seeks Canada’s approval for the use of Spikevax COVID-19 vaccine in children aged 6 to 11 years

0
193

Moderna has sought the approval of Canada for the use of the use of Spikevax COVID-19 vaccine in children 6 to 11 years of age.

“Today, Health Canada received a submission from Moderna seeking authorization for the use of its Spikevax COVID-19 vaccine in children 6 to 11 years of age. As with all COVID-19 vaccines, the Department will prioritize the review of this submission, while maintaining its high scientific standards for safety, efficacy and quality,” the Health Canada said in a statement.

The statement further addednthat Health Canada will only authorize the use of Spikevax in children if its independent and thorough scientific review of the data in the submission shows that the benefits of the vaccine outweigh the risks in this age group.

The assessment will include a detailed review of clinical trial results, as well as other evolving data and information about the health impacts of COVID-19 and variants of concern on children in Canada, the statement added.

This is the second submission Health Canada has received for the use of a COVID-19 vaccine in this younger age group. On October 18, 2021, Health Canada received a submission for the use of the Pfizer-BioNTech Comirnaty vaccine in children aged 5 to 11 years of age. The submission is currently under review.

Health Canada continues to closely monitor all safety and effectiveness data from real-world use of COVID-19 vaccines since their deployment in Canada and internationally, Health Canada said, adding that this includes data on the use of the Pfizer-BioNTech Comirnaty vaccine in children 5 to 11 years of age where it has already been authorized for use. If any new issues are identified with any of the COVID-19 vaccines authorized for use in Canada, the Department will take action as required.

Studies with the Moderna Spikevax vaccine are ongoing in children less than 6 years of age, and other manufacturers are also testing their vaccines in children of various age ranges. Health Canada expects to receive data for different age groups for review in the coming months.

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here